openPR Logo
Press release

Significant Reductions in Costly Pulmonary Complications with Use of Drug-Free Device

06-25-2018 10:26 AM CET | Health & Medicine

Press release from: Monaghan Medical Corporation

/ PR Agency: Star One PR
Significant Reductions in Costly Pulmonary Complications with

Plattsburgh, NY, USA -- Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA® oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.(1) The retrospective database analysis including 288 patients undergoing cardiac, thoracic or upper abdominal surgery suggests that use of the AEROBIKA® OPEP device in addition to standard of care (incentive spirometry, IS) was associated with fewer re-hospitalizations, shorter hospital stays and lower costs compared with patients using standard of care alone.

At 30 days post-discharge, significantly fewer patients in the AEROBIKA® OPEP device cohort were re-hospitalized (13.9 vs. 22.9%; p=0.042), and mean length of hospital stay was significantly shorter (1.25±4.04 days vs. 2.60±8.24 days; p=0.047) compared with the IS cohort. Costs due to hospitalizations were 80% lower in the AEROBIKA® OPEP device group (p=0.001).

The burden of PPCs, especially in patients undergoing abdominal, thoracic or cardiac surgery, is substantial:

• death rate is higher compared with patients who don't have PPCs (at 30 days mortality is up to 10 times higher, and at 90 days up to 20 times higher)

• resource use and costs are significantly increased (mainly due to longer length of hospital stay); a US database study of over 700,000 patients predicted that PPCs could lead to an additional 9,500 deaths, 92,000 extra ICU admissions and overall added costs to the US of US$3.42 billion.(2)

The causes of PPCs may be related to, among other things, shallow breathing and reduced airway clearance, therefore physical therapy techniques that increase lung volume and clearance have been recommended to reduce the risk and severity of PPCs. One such technique is incentive spirometry (IS), which encourages the patient to take long, slow breaths by inhaling through a device to raise a ball or piston.(3) The use of IS is common in clinical practice although there appears to be little evidence to support its value.(3,4) Another commonly used intervention to prevent and treat PPCs is positive expiratory pressure (PEP) therapy, which involves breathing against expiratory resistance.

The AEROBIKA® OPEP device is an easy-to-use, drug-free oscillating positive expiratory pressure (OPEP) device; when the patient exhales through the device, intermittent resistance creates a unique pressure-oscillation dynamic, which expands the airways and helps expel mucus to the upper airways where it can be coughed out. Clinical trial and real-world data have shown that the AEROBIKA® OPEP device increases lung volume, reduces hyperinflation and improves airway clearance in patients with COPD(5) or bronchiectasis,(6) as well as reducing exacerbations in patients with COPD.(7) These observations suggested a potential value for the device in preventing PPCs, leading the authors to conduct this retrospective real-world database study.

Co-author Dominic Coppolo, MBA, RRT, FAARC, Vice President Clinical Strategy and Development, commented that "based on the study findings, and taking into consideration both the low cost and low risk safety profile of the AEROBIKA® OPEP device, I would suggest that it could be beneficial to include as standard of care in all such post-operative patients", noting that future studies are warranted to further define the benefits. He went on to add "The fact that patients in the AEROBIKA® OPEP device group in our study incurred lower healthcare costs in the 30-day period following discharge (mainly as a result of fewer complications requiring readmission) is particularly relevant as providers and insurers look to reduce early rehospitalization."

Words or phrases accompanied by ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation. © 2018 Monaghan Medical Corporation.

1. Burudpakdee C, Near AM, Huang H, Coppolo D, Kushnarev V, Suggett J. A Real-World Evidence Study Assessing the Impact of Adding the Aerobika® Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients. Pulmonary Therapy. 2018.
2. Linde-Zwirble W, Bloom J, Mecca R, Hansell D. Postoperative pulmonary complications in adult elective surgery patients in the US: severity, outcomes and resources use. Critical Care. 2010;14 (Suppl 1):P210.
3. Restrepo RD, Wettstein R, Wittnebel L, Tracy M. Incentive spirometry: 2011. Respiratory care. 2011;56(10):1600-1604.
4. Carvalho CR, Paisani DM, Lunardi AC. Incentive spirometry in major surgeries: a systematic review. Revista brasileira de fisioterapia (Sao Carlos (Sao Paulo, Brazil)). 2011;15(5):343-350.
5. Svenningsen S, Paulin GA, Sheikh K, et al. Oscillatory Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease. COPD. 2016;13(1):66-74.
6. Svenningsen S, Guo F, McCormack DG, Parraga G. Noncystic Fibrosis Bronchiectasis: Regional Abnormalities and Response to Airway Clearance Therapy Using Pulmonary Functional Magnetic Resonance Imaging. Academic radiology. 2017;24(1):4-12.
7. Burudpakdee C, Seetasith A, Dunne P, et al. A real-world study of 30-day exacerbation outcomes in chronic obstructive pulmonary disease (COPD) patient managed with Aerobika® OPEP. Pulmonary Therapeutics. 2017.
8. Khoudigian-Sinani S, Kowal S, Suggett JA, Coppolo DP. Cost-effectiveness of the Aerobika® oscillating positive expiratory pressure device in the management of COPD exacerbations. International journal of chronic obstructive pulmonary disease. 2017;12:3065-3073.

About Monaghan Medical Corporation (MMC, USA)
MMC offers leading aerosol drug delivery devices and respiratory management products including AEROECLIPSE® II BAN, AEROCHAMBER PLUS® aVHC and the AEROBIKA® OPEP device exclusively in the United States. MMC's strength lies in product development around core capabilities in mechanical design complimented by collaboration with a state-of-the-art aerosol research laboratory. MMC focuses on developing cost-efficient, outcome-based solutions for its customers. (http://www.monaghanmed.com)

About the AEROBIKA® Device
The AEROBIKA® OPEP device (http://www.monaghanmed.com/aerobika) is a hand-held, robust, easy-to-use, drug-free oscillating positive expiratory pressure (OPEP) device designed to help expel mucus from the lungs, expand airways and enhance drug deposition. When the patient exhales through the device, intermittent resistance creates a unique pressure-oscillation dynamic, which expands the airways, helps expel the mucus to the upper airways where it can be coughed out. The AEROBIKA® OPEP device is designed to function independent of angle of use or flow rate, and allows for a direct aerosol pathway for patients using a nebulizer for medication delivery. The AEROBIKA® OPEP device has been shown to significantly improve forced vital capacity (FVC), 6-min walk distance (6MWD), and St. George's Respiratory Questionnaire (SGRQ) score in COPD patients.8 The AEROBIKA® OPEP device is available in the US via Monaghan Medical Corporation, and in Canada, Mexico, and select European countries including the UK and Germany through Trudell Medical International (http://www.trudellmed.com). (http://www.monaghanmed.com/Aerobika-OPEP)

About the study
This retrospective database study utilized patient data stored in IQVIA's proprietary Hospital Charge Detail Master (CDM) database. The CDM database manages daily transactional patient charges from over 650 hospitals from 46 states in the USA, covering 7 million annual inpatient stays and 60 million annual outpatient visits. A total of 887 cardiac, thoracic or upper abdominal surgery patients hospitalized between 1 September 2013 and 30 April 2017 were identified to have used the AEROBIKA® OPEP device (in addition to standard of care, incentive spirometry), of whom 144 matched the selection criteria. The comparison cohort was 144 propensity-score matched subjects who had used IS alone.

For clinical inquiries, please contact:
Dominic P. Coppolo, MBA, RRT, FAARC
Vice President Clinical Strategy and Development
Monaghan Medical Corporation
5 Latour Ave # 1600, Plattsburgh, NY 12901
1-800-343-9071

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Significant Reductions in Costly Pulmonary Complications with Use of Drug-Free Device here

News-ID: 1095214 • Views: 266

More Releases from Monaghan Medical Corporation

New Published Evidence Reinforces the Importance of Device Choice in Asthma Cont …
Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control. Plattsburgh, NY, USA -- A recent article in Pulmonary Pharmacology and Physiology[1] provides in vitro evidence that the AEROCHAMBER PLUS® FLOW-VU® valved holding chamber (or spacer) delivers aerosolized drug more effectively than other chambers, a view further supported in a new literature review published in Therapeutic Advances in Respiratory Disease.[2] The use of spacers
Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control
Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Plattsburgh, NY, USA -- Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Research has shown that even when using the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.[1] A landmark
Significant Cost Reduction in COPD Care With Simple, Drug-free Device
Aerobika® OPEP device proves to be a cost-effective treatment option in the management of post-exacerbation COPD patients. Plattsburgh, NY, USA -- The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device (Monaghan Medical Corporation) is a cost-effective treatment option in the management of COPD exacerbations, according to a study published October 20th in the International Journal of COPD.[1] This study, which used data from the published literature and national fee schedules to model
Monaghan Medical Corporation Receives Innovative Technology Designation from Viz …
Designation recognizes products that bring improvements to the health care industry. Plattsburgh, NY, USA -- Monaghan Medical Corporation announced its AEROBIKA® Oscillating Positive Expiratory Pressure (OPEP) device (http://www.aerobika.us) has received a 2017 Innovative Technology designation from Vizient, Inc. (http://www.vizientinc.com), the largest member-driven health care performance improvement company in the country. The designation was based on direct feedback from hospital experts who interacted with the AEROBIKA® OPEP device at the Vizient Innovative

All 5 Releases


More Releases for PEP

Global Metallized Rollstock PEP Film Market Huge Growth Opportunity between 2020 …
LP INFORMATION recently released a research report on the Metallized Rollstock PEP Film market analysis, which studies the Metallized Rollstock PEP Film's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "Metallized Rollstock PEP Film Market 2020-2025" Research Report categorizes the global Metallized Rollstock PEP Film market by key players, product type, applications and regions,etc. The report also covers the latest
Airway Clearance Systems Market Key Players PEP, OPEP, IPV, and HCFWO devices
Persistence Market Research (PMR) has published a new report on airway clearance systems. The report has been titled, “Airway Clearance Systems Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” The demand for airway cleaners is expanding with the improvement in the reimbursement structure and the growing concerns on a healthy living. In order to meet the growing requirement, the companies operating in the market have pulled up their socks. Request for
Automotive Agile PEP 2018 - Mastering Complexity to Foster Innovation
Berlin, September 11, 2018 – The Automotive Agile PEP is an international business event on the integration of agile principles, methods as well as practices into hardware and software development processes in the automotive industry. From November 25. – 27, 2018 the interactive conference in Berlin will see the leading automotive Hardware Developers, Product Development Experts, Project & Process Managers, Engineering & R&D Managers the daily challenges and approaches on
Driving Innovation: E-commerce Automotive Market By Key Vendors: Amazon, Alibaba …
Qyresearchreports include new market research report E-commerce Automotive to its huge collection of research reports. This report focuses on the global E-commerce Automotive status, future forecast, growth opportunity, key market and key players. The study objectives are to present the E-commerce Automotive development in United States, Europe and China. In 2017, the global E-commerce Automotive market size was million US$ and it is expected to reach million US$ by the end of
New luxury rental "Villa X" in Ibiza, Can Pep Simó/Cap Martinet for rent
Vacay Villas Ibiza S.L. is proud to announce its newest member in their rental villa family: Welcome to the newly built 360° panoramic-view luxury »Villa X«, situated on a private plot of about 1500 m2 on a hill of the exclusive neighborhood of Can Pep Simó/Cap Martinet, Ibiza. The company is accepting summer 2018 holiday reservations from now on. Prices are ranged between 4.000 EUR per week in April up to 12.500
KYC2020 adds Politically Exposed Person (PEP) from over 198 Countries
Chicago, IL – June 15, 2016 - KYC2020 (kyc2020.com), the single source for comprehensive Know Your Customer (KYC) & Anti-Money Laundering (AML) compliance regimes, today announced support for screening Politically Exposed Person (PEP) from over 198 Countries to its services platform and screening engine. KYC2020’s target customers include companies required by regulations to screen all customers under an AML regime such as MTO/MSBs, Real Estate, FX dealers, and Banks,